Skip to content
value.today

Stratos Genomics Inc.

🇺🇸 Seattle, Washington, USABiotechnologyFounded 2008
Total raised
$59 M
5 rounds on record
Latest round
$20 M
Nov 2017
First round on record
Jul 2010
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Stratos Genomics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2017$20 MNo. 5$10 to $50 million

Stratos Genomics Inc.: Raise no. 5, Nov 2017

Investors in this round

4 investors had bought by the notice of Jan 9, 2018: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Washington

People named in the notice

  • Mark Kokoris · Executive Officer, Director
  • Harold Kawaguchi · Director
  • Heiner Dreismann · Director
  • Lee Huntsman · Director
  • Robert McRuer · Director
  • Stephen Rose · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark Kokoris, President & CEO. Source: SEC Form D, newest notice filed Jan 9, 2018. Read the notice at the SEC.

equitySEC
Apr 2014$30 MNo. 4$10 to $50 million

Stratos Genomics Inc.: Raise no. 4, Apr 2014

Investors in this round

2 investors had bought by the notice of Jun 17, 2015: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Washington

People named in the notice

  • Allan Stephan · Executive Officer, Director
  • Bob McRuer · Executive Officer, Director
  • Harold Kawaguchi · Executive Officer, Director
  • Mark Kokoris · Executive Officer, Director
  • Heiner Dreismann · Director
  • Lee Huntsman · Director
  • Stephen Rose · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Allan H. Stephan, Ceo. Source: SEC Form D and 1 amendment, newest notice filed Jun 17, 2015. Read the notice at the SEC.

equitySEC
Sep 2013$2 MNo. 3$2 to $10 million

Stratos Genomics Inc.: Raise no. 3, Sep 2013

Investors in this round

1 investor had bought by the notice of Sep 6, 2013: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Washington

People named in the notice

  • Allan Stephan · Executive Officer, Director
  • Bob McRuer · Executive Officer, Director
  • Harold Kawaguchi · Executive Officer, Director
  • Mark Kokoris · Executive Officer, Director
  • Heiner Dreismann · Director
  • Lee Huntsman · Director
  • Stephen Rose · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Allan H. Stephan, President and CEO. Source: SEC Form D, newest notice filed Sep 6, 2013. Read the notice at the SEC.

equitySEC
Oct 2012$2 MNo. 2$2 to $10 million

Stratos Genomics Inc.: Raise no. 2, Oct 2012

Investors in this round

1 investor had bought by the notice of Oct 16, 2012: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $4 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Washington

People named in the notice

  • Allan Stephan · Executive Officer, Director
  • Harold Kawaguchi · Executive Officer, Director
  • Mark Kokoris · Executive Officer, Director
  • Bob McRuer · Director
  • Heiner Dreismann · Director
  • Lee Huntsman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering Amount does not include warrants issued to certain Investors to purchase up to 128,000 shares of Common Stock.”

Signed by Allan H. Stephan, President and CEO. Source: SEC Form D, newest notice filed Oct 16, 2012. Read the notice at the SEC.

equitySEC
Jul 2010$5 MNo. 1$2 to $10 million

Stratos Genomics Inc.: Raise no. 1, Jul 2010

Investors in this round

19 investors had bought by the notice of Jun 7, 2016: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$29,999
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Washington

People named in the notice

  • Lee Huntsman · Executive Officer, Director
  • Mark Kokoris · Executive Officer, Director
  • Robert McRuer · Executive Officer, Director
  • Allan Stephan · Director
  • Harold Kawaguchi · Director
  • Heiner Dreismann · Director
  • Stephen Rose · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Dr. Heiner Dreismann · Seattle, WashingtonSold in WA

Remarks in the notice

  • On fees: “Finders' Fees, represents a warrant to purchase common shares issued to the placement agent pursuant to the terms of the subject financing.”
  • On the amounts: “Total Offering Amount includes (i) principal and accrued interest on previously issued convertible notes that converted into equity; (ii) aggregate exercise price of warrants issued upon conversion of the notes; and (iii) warrants issued as finders' fees.”

Signed by Mark Kokoris, President and CEO. Source: SEC Form D and 1 amendment, newest notice filed Jun 7, 2016. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Stratos Genomics Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2018).

    SEC Form D · Jan 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2018

That is all the official record says: Stratos Genomics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Stratos Genomics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 19 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Stratos Genomics Inc.
NameRoleNamed in
Mark KokorisExecutive officerJan 2018
Lee HuntsmanExecutive officerJun 2016
Robert McRuerExecutive officerJun 2016
Allan StephanExecutive officerJun 2015
Bob McRuerExecutive officerJun 2015
Harold KawaguchiExecutive officerJun 2015
Harold KawaguchiDirectorJan 2018
Heiner DreismannDirectorJan 2018
Lee HuntsmanDirectorJan 2018
Mark KokorisDirectorJan 2018
Robert McRuerDirectorJan 2018
Stephen RoseDirectorJan 2018
Allan StephanDirectorJun 2016
Bob McRuerDirectorJun 2015